Fig. 2. Response to repeat dosing of chimpanzees with ARC-520.

Slides:

Advertisements

Similar presentations

Fig. 1 CSF1 is increased in blood of melanoma patients and correlates with disease progression. CSF1 is increased in blood of melanoma patients and correlates.

Advertisements

LTB4 production is elevated in preclinical and clinical lymphedema

Fig. 2. Effects of AZD4785 on proliferation and MAPK pathway signaling in KRAS mutant and wild-type cancer cells in vitro. Effects of AZD4785 on proliferation.

Fig. 5. Protective efficacy of the combination of PGT121 + PGDM1400 against a mixed SHIV challenge in rhesus monkeys. Protective efficacy of the combination.

Fig. 5. Correlation between CD34+CD45RA−CD90+ cell dose, engraftment success, and onset of neutrophil/platelet recovery in nonhuman primates. Correlation.

Fig. 2. Bestatin treatment improves tail anatomy and restores lymphatic function. Bestatin treatment improves tail anatomy and restores lymphatic function.

Effects of highly concentrated SFN provided as BSE in T2D patients

Fig. 8. Gene and protein changes in ALK-dependent STING pathways in human sepsis. Gene and protein changes in ALK-dependent STING pathways in human sepsis.

Fig. 5. Correlation of tail and long bone growth velocities with Cxm serum concentrations in mice. Correlation of tail and long bone growth velocities.

Fig. 4. Liver HBV mRNA paired-end sequencing reads in HBeAg-positive and HBeAg-negative chimpanzees. Liver HBV mRNA paired-end sequencing reads in HBeAg-positive.

Fig. 4. Specific antibiotics reduce fecal biomass in mice and humans.

Fig. 4. Hydrogel particle size and gelation mechanism.

In vivo prophylactic and therapeutic efficacy of C12G6 in mice

Fig. 2. Engraftment of CART-EGFRvIII and cytokine modulation in the peripheral blood. Engraftment of CART-EGFRvIII and cytokine modulation in the peripheral.

Fig. 3. Serum HBsAg and liver HBV mRNA reduction in chimpanzees dosed with ARC-520. Serum HBsAg and liver HBV mRNA reduction in chimpanzees dosed with.

Fig. 8. mRIPO elicits neutrophil influx followed by DC and T cell infiltration into tumors. mRIPO elicits neutrophil influx followed by DC and T cell infiltration.

Fig. 4 Topical application of SAAP-148 ointment eradicates acute and established infections of MRSA and A. baumannii from the skin. Topical application.

Fig. 2. GPC3 expression in normal and tumor tissues.

Bio-AMS enhances the activity of rifampicin and ethambutol in vitro

Fig. 5. Antitumor efficacy of ERY974 in immunocompetent human CD3 transgenic mice. Antitumor efficacy of ERY974 in immunocompetent human CD3 transgenic.

Increased ADMA in pregnancy is associated with SGA birth outcomes

Fig. 4. In vivo analysis of slpA mutant in the Syrian Golden hamster.

Fig. 4. Antitumor efficacy of ERY974 against various cancer types.

Fig. 4. Geographic atrophy progression in CFI risk-allele carriers and risk-negative subpopulations after monthly lampalizumab treatment. Geographic atrophy.

Fig. 1. IS mediates a hyperthrombotic uremic phenotype in an AHR-dependent manner across CKD stages. IS mediates a hyperthrombotic uremic phenotype in.

Dot plots of trisomic versus fetal fractions for cohorts 1 and 2

Fig. 7 Gel scaffold for inhibition of postsurgical recurrence of B16F10 tumors. Gel scaffold for inhibition of postsurgical recurrence of B16F10 tumors.

Fig. 1. Serum HBsAg, HBcrAg, and HBeAg reduction in human patients treated with a single dose of ARC-520. Serum HBsAg, HBcrAg, and HBeAg reduction in human.

Fig. 2. Effects of SFN in mouse hepatocytes and in rat models of diet-induced glucose intolerance. Effects of SFN in mouse hepatocytes and in rat models.

Fig. 3. Applying the rapid test to analyze human patient sera.

Fig. 4. MATE1 transcription in RCC.

Fig. 6. Safety assessment in cynomolgus monkey.

Fig. 6 ROC curves of mCCNA1 and mVIM assayed on esophageal balloon samplings of the distal esophagus. ROC curves of mCCNA1 and mVIM assayed on esophageal.

Fig. 2. Best model fits. Best model fits. Illustration of the best model fits for the (A) basic, (B) continuous, and (C) cluster models. See Table 1 and.

Fig. 5. MasSpec Pen analysis of an HGSC tissue sample with mixed histologic composition. MasSpec Pen analysis of an HGSC tissue sample with mixed histologic.

Fig. 3 Liver stiffness and NT-proBNP concentration after treatment with miridesap followed by dezamizumab. Liver stiffness and NT-proBNP concentration.

Fig. 4. BET inhibition sensitizes HR-proficient tumors to PARPi treatment in vivo. BET inhibition sensitizes HR-proficient tumors to PARPi treatment in.

Fig. 1. Experimental workflow of the dAST method and computationally estimated operational space. Experimental workflow of the dAST method and computationally.

Representative CT and PET/CT images of three patients with NSCLCs

Fig. 7 BRD0705 impairs colony formation in AML cell lines and patient cells and shows in vivo efficacy in multiple AML mouse models. BRD0705 impairs colony.

Fig. 7 Human study design for device testing.

Fig. 2 Whisker deprivation accelerates and enhances behavioral recovery after right S1FP photothrombosis. Whisker deprivation accelerates and enhances.

Fig. 1. Map showing the study catchment area in the East of England.

Fig. 5 Local gel scaffold for T cell memory response.

Fig. 3 M7824 inhibits tumor growth and metastasis and provides long-term antitumor immunity. M7824 inhibits tumor growth and metastasis and provides long-term.

Fig. 4. Improved tumor response to docetaxel in TNBC and trastuzumab in HER2-amplified PDX models with the addition of S Improved tumor response.

Fig. 7. NAC in breast cancer patients promotes TMEM assembly and increased MENAINV expression. NAC in breast cancer patients promotes TMEM assembly and.

Fig. 2 Analysis of CLL lymph nodes.

PAAND is driven by local inflammasome activation and IL-1β production

Fig. 3 Hepatic HBV envelope RNA and protein expression levels in HBVRplRag−/− mice 7 days (1 week) and 8 to 24 weeks after adoptive transfer with WT or.

Fig. 4. The effect of single-dose rozanolixizumab on the concentration of IgG subtypes in healthy subjects. The effect of single-dose rozanolixizumab on.

Fig. 4. Efficacy of C12G6 compared with and in combination with oseltamivir in mice. Efficacy of C12G6 compared with and in combination with oseltamivir.

Fig. 6. Analysis of SHIV-325c V1V2 envelope sequences in breakthrough infections. Analysis of SHIV-325c V1V2 envelope sequences in breakthrough infections.

Fig. 6. CXM correlates with age and growth velocity.

Fig. 5. Mapping of HBV S transcripts from HBeAg-positive and HBeAg-negative chimpanzees. Mapping of HBV S transcripts from HBeAg-positive and HBeAg-negative.

Fig. 7 Analysis of the bacterial nidus within tissue abscesses by MALDI IMS demonstrates a paucity of calprotectin signal. Analysis of the bacterial nidus.

Fig. 7 Vaccine-induced influenza-specific B cells are not maintained in peripheral blood. Vaccine-induced influenza-specific B cells are not maintained.

IIV induces CD21hiCD27+ and CD21loCD27+ influenza-specific B cells

Fig. 5 Early and modest immune response at day 3 after exposure in Delayed animals. Early and modest immune response at day 3 after exposure in Delayed.

Fig. 5 Treatment with an OX40 agonist antibody of 3-week-old HBVtgRag−/− mice or mice with chronic HBV disease results in an altered immune response to.

Fig. 4. Clearance of 12-mer-1 from a nonhuman primate model.

Fig. 4 cTFH1 cells correlate with a boosting of influenza-specific memory B cells. cTFH1 cells correlate with a boosting of influenza-specific memory B.

Fig. 5. Rises in RSV PRNT during the surveillance period.

Fig. 3. The effect of VRC01 infusion on virus load in plasma and blood CD4 T cells during ART. The effect of VRC01 infusion on virus load in plasma and.

Fig. 2 Preserved long-term functionality of the TEHVs over 1-year follow-up as assessed by ICE and cardiac MRI flow measurements. Preserved long-term functionality.

Fig. 3 Liver stiffness and NT-proBNP concentration after treatment with miridesap followed by dezamizumab. Liver stiffness and NT-proBNP concentration.

Fig. 2. Effects of SFN in mouse hepatocytes and in rat models of diet-induced glucose intolerance. Effects of SFN in mouse hepatocytes and in rat models.

Fig. 1. Detection of circulating tumor DNA in CRPC patients.

Fig. 1 Study design and antibody pharmacokinetics.

Fig. 1 ZMAb improves survival of EBOV-challenged NHPs

Presentation transcript:

Fig. 2. Response to repeat dosing of chimpanzees with ARC-520. Response to repeat dosing of chimpanzees with ARC-520. (A) After a prestudy evaluation, nine chimpanzees began daily oral NUC dosing. After a variable NUC lead-in period to reduce viremia, NUC treatment continued concomitant with Q4W dosing of ARC-520 that began on day 1. Dosing days are indicated by vertical dashed lines. Blood samples were collected periodically throughout the study, and serum HBV DNA (B), HBeAg (C), and HBsAg (D and E) were measured and are shown for individual animals. (F) Mean log10 change in HBsAg for the 8 weeks preceding the first dose of ARC-520 and during ARC-520 treatment of four HBeAg-positive (●) and four HBeAg-negative (□) and in the HBeAg transitional chimpanzee (▲). BLD, below the limit of detection. *, chimpanzee 89A008 transitioned from HBeAg-positive to HBeAg-negative during the NUC lead-in period. Boxes in (B) and (C) indicate the first day of daily ETV dosing. Christine I. Wooddell et al., Sci Transl Med 2017;9:eaan0241 Published by AAAS